Jefferies initiated coverage of Veracyte (VCYT) with a Buy rating and $45 price target The firm sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequencing costs, but also “ongoing polarization between the leaders and laggards.” Jefferies views Caris Life Sciences and Veracyte as “compelling stocks” given their profitability, pipelines and valuations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity
- Veracyte price target lowered to $45 from $50 at Guggenheim
- Veracyte Appoints Kevin Haas as Chief Technology Leader
- Veracyte names Kevin Haas as Chief Development and Technology Officer
- Veracyte price target lowered to $37 from $48 at Morgan Stanley